Yahya Tamimi1, Sheikha Al-Harthy1, Ibrahim Al-Haddabi2, Mohammed Al-Kindi1, Hamza Babiker1, Mansour Al-Moundhri3, Ikram Burney4. 1. Departments of Biochemistry, College of Medicine & Health Sciences, Sultan Qaboos University; 2. Departments of Pathology, Sultan Qaboos University Hospital, Muscat, Oman. 3. Medicine, College of Medicine & Health Sciences, Sultan Qaboos University; 4. Medicine, Sultan Qaboos University Hospital, Muscat, Oman.
Abstract
OBJECTIVES: Mutations/deletions affecting the TP53 gene are considered an independent marker predicting a poor prognosis for patients with diffuse large B-cell lymphoma (DLBCL). A cohort within a genetically isolated population was investigated for p53 mutation/deletion status. METHODS: Deoxyribonucleic acid (DNA) samples were extracted from 23 paraffin-embedded blocks obtained from DLBCL patients, and subjected to polymerase chain reaction (PCR) amplification and sequencing of exons 4-9 of the p53 gene. RESULTS: While 35% of patients analysed displayed allelic deletions (P <0.01), immunohistochemical analysis revealed a mutation rate of 69.5%. It is noteworthy that the rate of p53 mutations/deletions in this small cohort was found to be higher than that previously reported in the literature. Interestingly, patients with p53 mutations displayed a better overall survival when compared to those without. The survival of patients treated with rituximab-containing combination chemotherapy was significantly better than those who did not receive rituximab (P <0.05). Furthermore, a modelling analysis of the deleted form of p53 revealed a huge structural change affecting the DNA-binding domain. CONCLUSION: The TP53 mutation/deletion status plays a role in mechanism(s) ruling the pathogenesis of DLBCL and may be useful for stratifying patients into distinct prognostic subsets.
OBJECTIVES: Mutations/deletions affecting the TP53 gene are considered an independent marker predicting a poor prognosis for patients with diffuse large B-cell lymphoma (DLBCL). A cohort within a genetically isolated population was investigated for p53 mutation/deletion status. METHODS: Deoxyribonucleic acid (DNA) samples were extracted from 23 paraffin-embedded blocks obtained from DLBCL patients, and subjected to polymerase chain reaction (PCR) amplification and sequencing of exons 4-9 of the p53 gene. RESULTS: While 35% of patients analysed displayed allelic deletions (P <0.01), immunohistochemical analysis revealed a mutation rate of 69.5%. It is noteworthy that the rate of p53 mutations/deletions in this small cohort was found to be higher than that previously reported in the literature. Interestingly, patients with p53 mutations displayed a better overall survival when compared to those without. The survival of patients treated with rituximab-containing combination chemotherapy was significantly better than those who did not receive rituximab (P <0.05). Furthermore, a modelling analysis of the deleted form of p53 revealed a huge structural change affecting the DNA-binding domain. CONCLUSION: The TP53 mutation/deletion status plays a role in mechanism(s) ruling the pathogenesis of DLBCL and may be useful for stratifying patients into distinct prognostic subsets.
Authors: K Grønbaek; P de Nully Brown; M B Møller; T Nedergaard; E Ralfkiaer; P Møller; J Zeuthen; P Guldberg Journal: Leukemia Date: 2000-10 Impact factor: 11.528
Authors: Fábio R Kerbauy; Gisele W B Colleoni; Sara T O Saad; Maria Regina Regis Silva; Antonio Correa Alves; Kátia C C Aguiar; Dulcinéia M Albuquerque; Jörg Kobarg; Maria Tereza Seixas; José Kerbauy Journal: Leuk Lymphoma Date: 2004-10
Authors: Anneke G Bosga-Bouwer; Anke van den Berg; Eugenia Haralambieva; Debora de Jong; Ronald Boonstra; Philip Kluin; Eva van den Berg; Sibrand Poppema Journal: Hum Pathol Date: 2006-05 Impact factor: 3.466
Authors: H Stöcklein; J Smardova; J Macak; T Katzenberger; S Höller; S Wessendorf; G Hutter; M Dreyling; E Haralambieva; U Mäder; H K Müller-Hermelink; A Rosenwald; G Ott; J Kalla Journal: Oncogene Date: 2007-11-05 Impact factor: 9.867
Authors: Elena N Voropaeva; Tatyana I Pospelova; Mikhail I Voevoda; Vladimir N Maksimov; Yuriy L Orlov; Olga B Seregina Journal: BMC Med Genomics Date: 2019-03-13 Impact factor: 3.063